$BIAFJun 22, 2026, 12:00 PMAI processed
bioAffinity siRNAs selectively kill squamous/basal skin cancer cells in vitro while sparing normal skin
AI Summary
BioAffinity (BIAF, BIAFW) reported preclinical in vitro data showing proprietary siRNAs targeting CD320 and LRP2 selectively impaired proliferation or were cytotoxic to squamous and basal skin cancer cell lines while leaving non-cancerous skin cells unaffected, supporting pursuit of a topical treatment approach. The data will be presented at RNATx (June 24–26), but results are limited to controlled lab studies, no IND has been filed and the findings have not been tested in humans.
Positives
- siRNAs targeting CD320 and LRP2 were selectively cytotoxic or antiproliferative to squamous and basal skin cancer cell lines in vitro
- Non-cancerous primary skin cells were reportedly unaffected in the same experiments
- Findings to be presented at the RNATx 2026 symposium (visibility to RNA therapeutics community)
Negatives
- Results are preclinical in vitro only and may not translate to animal models or human trials
- No IND has been filed and no human testing has been conducted
- Therapeutic program is early-stage despite a related U.S. patent